Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones

Viatris Inc. (NASDAQ:VTRS) is one of the top cheap stocks under $20 to buy now. On December 18, Viatris Inc. (NASDAQ:VTRS) announced four recent regulatory milestones spread across all stages of the company’s global pipeline. It stated that the FDA approved the company’s octreotide acetate for injectable suspension, which is a generic version of Sandostatin® LAR Depot and indicated for treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for acromegaly, profuse watery diarrhea associated with Vasoactive Intestinal Peptide secreting tumors, and severe diarrhea/flushing episodes associated with metastatic carcinoid tumors.

Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves

Viatris Inc. (NASDAQ:VTRS) also reported that the US FDA granted acceptance for review of the New Drug Application (NDA) for the company’s investigational low dose estrogen weekly patch, comprising 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol, for contraception. In addition, the US FDA cleared the company’s Investigational New Drug (IND) application for MR-146, an Enriched Tear FilmTM (ETF) Adeno-Associated Virus (AAV) gene therapy candidate for the treatment of people with neurotrophic keratopathy (NK). The company has plans to begin a Phase 1 / 2 clinical trial, CORVITA, for MR-146 in patients with NK in H1 2026.

Viatris Inc. (NASDAQ:VTRS) also reported that the Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted its Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome (OSAS), and the company is set to submit a J-NDA for narcolepsy by the end of the year.

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company’s medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women’s healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VTRS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.